Live financial news intelligence

Track market-moving stories before they get noisy

Real-time pulse of financial headlines curated from 5 premium feeds.

Latest market signal Czech Filtered by asset GEHC

Coverage 92,717 Raw stories ingested 8,002 rewritten in CS_CZ • 0 to rewrite (last 2 days).

Symbols 2,728 Assets with fetched stories

Cryptocurrencies BTC 4,284 ETH 3,097 SOL 1,755 XRP 1,707 USDC 969 HYPE 835

Stocks SPCX 882 MU 724 NVDA 694 MSFT 564 GOOGL 538 TSLA 506

Commodities GOLD 159 SILVER 93 OIL 51 PLATINUM 5 PALLADIUM 2 COPPER 1

Forex EURUSD 148 GBPUSD 143 USDCAD 51 USDJPY 37 AUDUSD 33 NZDUSD 23

1,682 with rewritten stories in CS_CZ • Hot assets ranked by fetched stories.

Agents 7 waiting Pipeline agents

FMP Stock News Fetch every minute 43s ago
FMP Forex News Fetch every 5 min 43s ago
CoinGecko News Fetch every 5 min 43s ago
FIO Stock News Fetch every 10 min 9m ago
Patria Stock News Fetch every 10 min 9m ago
Editorial rewrite Rewrite every minute 43s ago
Asset sync Assets every 1 hour 49m ago

Latest coverage

Market News Feed

Scan headlines quickly, then expand any story for source context.

Category Source Ticker

Relevance

Clear

Details	Date	Content	Source	Relevance
	Saved 2026-07-24 17:54 2d ago Published 2026-07-24 12:25 2d ago	GE HealthCare čeká růst tržeb, marže dál tlačí náklady GE HealthCare čeká ve 2. čtvrtletí růst tržeb o 5 % na 5,25 miliardy USD, ale marže a zisk na akcii (EPS) dál tlačí inflace, doprava, cla a vyšší vstupní náklady. GEHC GE HealthCare Technologies	FMP Stock News	78
Original source text Key Takeaways GEHC is expected to post healthy Q2 revenue growth, backed by imaging, diagnostics, and services demand.GEHC faces margin pressure from inflation, freight, tariffs, and higher input costs despite pricing actions.GEHC expects stronger second-half performance as efficiencies, pricing, and new products gain traction. GE HealthCare Technologies Inc. (GEHC - Free Report) is scheduled to report second-quarter 2026 results on July 29, before market open. In the last reported quarter, the company’s adjusted earnings per share (EPS) of 99 cents missed the Zacks Consensus Estimate by 7.48%. The company beat on earnings in three of the trailing four quarters and missed once, delivering an average surprise of 2.90%. Let’s check out the factors that might have shaped GEHC’s performance prior to the announcement. Factors Likely to Have Driven GEHC’s Q2 PerformanceGE HealthCare is expected to have delivered another quarter of healthy revenue growth, supported by resilient global demand for imaging equipment, continued strength in Pharmaceutical Diagnostics (PDx), and robust services performance. On its first-quarter earnings call, management had maintained its full-year organic revenue growth outlook of 3-4%, citing healthy order trends, a record $21.8 billion backlog, strong book-to-bill, and improving commercial execution despite a cautious view on China. However, profitability is likely to have remained under pressure from elevated inflation in memory chips, freight, oil and commodity costs, with management already guiding for low-single-digit adjusted EPS decline in the second quarter before improvement in the second half. Following the organizational restructuring, the newly created Advanced Imaging Solutions business is likely to have benefited from sustained demand for CT, X-ray, ultrasound and visualization products. Imaging demand should have been supported by Revolution Vibe cardiac CT systems, while Advanced Visualization Solutions likely continued to benefit from adoption of products, such as Vivid Pioneer and other AI-enabled platforms. Although Photonova Spectra photon-counting CT generated encouraging customer interest after regulatory approvals, revenue contribution is unlikely before 2027 due to typical installation timelines. Pharmaceutical Diagnostics is likely to have remained the company's strongest-performing business. Continued growth in contrast media, radiopharmaceuticals and molecular imaging, along with accelerating Flyrcado adoption and increasing Vizamyl demand driven by Alzheimer's imaging, likely supported another solid quarter. However, planned investments in the radiopharmaceutical pipeline and integration of recent acquisitions may have weighed on margin expansion. Patient Care Solutions likely remained the weakest segment, although management expects gradual improvement later in the year as large monitoring installations convert from backlog and the premium anesthesia platform approaches regulatory clearance. Lower first-half volume and ongoing tariff-related costs probably continued to weigh on segment profitability. On the margin front, the second quarter is expected to represent the peak impact from inflationary input costs, including memory chips and freight, while pricing actions and cost mitigation initiatives are likely to have provided only limited near-term relief because much of the second-quarter revenues probably originated from existing backlog. Adjusted EBIT margin and EPS are expected to have remained pressured, with a stronger recovery anticipated during the second half as pricing actions, operating efficiencies and new product momentum begin to offset inflationary pressures. GEHC’s Estimate PictureFor second-quarter 2026, the Zacks Consensus Estimate for revenues is pegged at $5.25 billion, implying an improvement of 5% from the prior-year quarter’s reported figure. The consensus estimate for EPS is pegged at $1.04, indicating a decrease of 1.9% from the prior-year period’s reported number. What Our Model Suggests for GE HealthCarePer our proven model, the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) increases the chances of an earnings beat. That is not the case here, as you will see below. Earnings ESP: GE HealthCare has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank stocks here. GEHC’s Share Price PerformanceSo far this year, GE HealthCare’s shares have lost 24.4% compared with the industry’s 22.5% decline. The S&P 500 has gained 9.2% during the said period. Image Source: Zacks Investment Research Stocks Worth a LookHere are some stocks from broader medical sector worth considering, as these have the right combination of elements to post an earnings beat this reporting cycle. Cardinal Health (CAH - Free Report) has an Earnings ESP of +1.24% and a Zacks Rank #2 at present. The company is set to release fourth-quarter fiscal 2026 results on Aug. 11. You can see the complete list of today’s Zacks #1 Rankstocks here. CAH’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 10.27%. The Zacks Consensus Estimate for CAH’s fourth-quarter EPS indicates an improvement of 16.4% from the year-ago reported figure. Henry Schein (HSIC - Free Report) has an Earnings ESP of +0.41% and a Zacks Rank of 2 at present. The company is scheduled to release second-quarter 2026 results on Aug. 4. HSIC’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 3.74%. The Zacks Consensus Estimate for HSIC’s second-quarter EPS implies an improvement of 10.9% from the year-ago reported figure. Agilent Technologies (A - Free Report) has an Earnings ESP of +1.02% and a Zacks Rank of 3 at present. A’s earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 1.61%. The Zacks Consensus Estimate for A’s third-quarter fiscal 2026 EPS reflects an improvement of 8% from the year-ago reported figure.
	Saved 2026-07-23 22:41 2d ago Published 2026-07-23 16:26 3d ago	GE HealthCare mění CFO a potvrzuje výhled CFO společnosti GE HealthCare Jay Saccaro odstoupí a dočasně ho nahradí controller a chief accounting officer George Newcomb. Firma zároveň za 2. čtvrtletí čeká růst tržeb o 5,7 % a potvrdila celoroční výhled. GEHC GE HealthCare Technologies	FMP Stock News	86
Original source text The logo of GE Healthcare is seen on their plant in the IDA (Industrial Development Agency) estate, in Carrigtwohill, County Cork, Ireland March 28, 2025. REUTERS/Clodagh Kilcoyne Purchase Licensing Rights, opens new tab CompaniesJuly 23 (Reuters) - GE HealthCare's (GEHC.O), opens new tab Chief Financial Officer Jay Saccaro will step down from his role to pursue an opportunity outside the medical technology industry, the ‌company said on Thursday, and also reported preliminary second-quarter results. The medical device maker named its current controller and chief accounting officer George Newcomb as interim CFO while it looks for a permanent replacement. Saccaro will remain with the company ⁠through August 14 to help with the handover. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here. Finance leadership reshuffles are taking place across the broader healthcare industry. Pfizer (PFE.N), opens new tab named an interim finance chief in June after Dave Denton announced his departure, and Baxter International (BAX.N), opens new tab appointed an interim CFO in March following Joel Grade's exit. GE HealthCare said it expects second-quarter revenue to increase 5.7% from a year earlier, or 3.5% on an organic basis, while it reaffirmed ‌its ⁠full-year forecast. Quarterly diluted and adjusted earnings are expected to come in higher than a year ago and above what the company had forecast earlier, GE HealthCare said. The Chicago-based firm previously lowered its full-year profit forecast ⁠when it reported first-quarter results, citing persistent inflation in memory-chip, oil and freight costs as well as tariff-related pressures stemming from the Middle East ⁠conflict. Newcomb brings more than three decades of finance experience to the interim role, the company said. He has been its ⁠controller since 2016 and took on the chief accounting officer position when the firm spun off from General Electric in 2023. Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Pooja Desai Our Standards: The Thomson Reuters Trust Principles., opens new tab
	Saved 2026-07-21 17:46 5d ago Published 2026-07-21 11:50 5d ago	GE HealthCare představila bezpečný vzdálený přístup k obrazovým datům GE HealthCare představila MIM Anyware, webovou platformu pro bezpečný vzdálený přístup k obrazovým datům bez lokální instalace softwaru. Cílí na spolupráci v reálném čase napříč onkologií a plánováním léčby. GEHC GE HealthCare Technologies	FMP Stock News	78
Original source text Key Takeaways GEHC's MIM Anyware enables secure, browser-based access to imaging data without local software installation.The platform supports real-time collaboration across oncology workflows, referrals and treatment planning.GE HealthCare also enhanced MIM Maestro and Contour ProtegeAI 2.0 with dose and AI tools. GE HealthCare Technologies Inc. (GEHC - Free Report) recently announced the launch of MIM Anyware, a web-based remote access platform designed to provide secure, healthcare system-controlled access to imaging data and the company's MIM software portfolio. The platform gives authorized users access to MIM software applications from virtually any location through a web browser without needing local software installation. The platform aims to improve collaboration, streamline imaging workflows and support faster clinical decision-making. Per management, research has demonstrated that effective collaboration among multidisciplinary teams is essential to deliver coordinated, patient-centered care. MIM Anyware was developed to transform how clinicians interact with medical imaging data in virtual settings. By providing secure browser-based access to imaging data and MIM's advanced analysis tools, the platform is intended to help clinicians to focus more on patient care. Likely Trend of GEHC Stock Following the NewsFollowing the announcement, GEHC shares dropped 0.4% at yesterday’s close. Year to date, the stock has lost 23.4% compared with the industry’s 21.1% decline. However, the S&P 500 has risen 8.7% in the same timeframe. GE HealthCare's launch of MIM Anyware is expected to strengthen its position in the cloud medical imaging platform market by expanding secure, browser-based access to imaging data and enabling real-time clinical collaboration across care teams. The platform's support for remote workflows, oncology applications and vendor-neutral interoperability aligns with the growing demand for cloud-enabled imaging solutions. This innovation is likely to increase customer adoption of GE HealthCare's portfolio of MIM software solutions. GEHC currently has a market capitalization of $28.69 billion. Image Source: Zacks Investment Research More on MIM AnywareAs healthcare providers manage large volumes of complex imaging data, traditional remote access solutions often struggle with siloed workstations, IT infrastructure requirements and compatibility with modern imaging environments. MIM Anyware overcomes these challenges by ensuring secure, high-performance remote access for physicians, physicists, dosimetrists and other clinicians to work together within the same MIM session. Teams can collaboratively review image registrations, perform routine clinical processing, deploy workflows and evaluate dose information in real time while improving cross-functional collaboration and workflow efficiency. The platform is much more valuable in cancer care, where treatment planning requires coordination among multidisciplinary teams. MIM Anyware supports radiation oncology workflows by facilitating consultations, referrals, tumor board discussions, clinician education and collaborative treatment planning. Alongside MIM Anyware, GEHC continues to improve its MIM software portfolio with solutions such as MIM Maestro and MIM Contour ProtégéAI+ 2.0. MIM Maestro now features a reirradiation and composite dose assessment workflow that allows visualization of prior treatment doses on current anatomy, accounts for radiobiological effects and evaluates multiple treatment strategies using rigid or deformable image registration within a unified workflow. Meanwhile, MIM Contour ProtégéAI+ 2.0 expands the company's AI-powered auto-contouring capabilities with new Magnetic Resonance Brain models and an enhanced Computed Tomography Male Pelvis model, improving contouring accuracy across key anatomical regions. Together, the vendor-neutral MIM software portfolio supports clinical applications across radiation oncology, radiology, nuclear medicine, theranostics, interventional radiology and urology. Industry Prospects Favoring the MarketGoing by the data provided by Research and Markets, the cloud medical imaging platform market was valued at $3.59 billion in 2025 and is projected to grow from $4.2 billion in 2026 to $7.86 billion by 2030, at a CAGR of 16.9% from 2026 to 2030. Factors like growing implementation of AI-enabled imaging tools, increasing migration toward hybrid cloud deployment models, rising demand for multi-facility image sharing and collaboration, expansion of healthcare digitalization initiatives in emerging economies and increasing focus on workflow automation in radiology departments are boosting the market’s growth. Other NewsRecently, GEHC announced a new research collaboration with Mayo Clinic to advance personalized cancer treatment through the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) study. The initiative will evaluate whether imaging, blood-based biomarkers and clinical data can help tailor radioligand therapy for patients with advanced prostate cancer, supporting more adaptive treatment decisions and expanding the use of theranostics. GEHC’s Zacks Rank & Key PicksCurrently, GEHC has a Zacks Rank #4 (Sell). Some better-ranked stocks from the broader medical space are West Pharmaceutical (WST - Free Report) , Intuitive Surgical (ISRG - Free Report) and Cardinal Health (CAH - Free Report) . West Pharmaceutical, currently sporting a Zacks Rank #1 (Strong Buy), reported first-quarter 2026 earnings per share (EPS) of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. You can see the complete list of today’s Zacks #1 Rank stocks here. West Pharmaceutical has an estimated long-term earnings growth rate of 14.4%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 19.4%. Intuitive Surgical, currently carrying a Zacks Rank #2 (Buy), reported second-quarter 2026 adjusted EPS of $2.80, which beat the Zacks Consensus Estimate by 12.9%. Revenues of $2.89 billion surpassed the Zacks Consensus Estimate by 3.1%. Intuitive Surgical has an estimated long-term earnings growth rate of 14.3%. ISRG’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.5%. Cardinal Health, currently carrying a Zacks Rank #2, reported a third-quarter fiscal 2026 adjusted EPS of $3.17, which beat the Zacks Consensus Estimate by 13.2%. Revenues of $60.94 billion missed the Zacks Consensus Estimate by 2.3%. Cardinal Health has an estimated long-term earnings growth rate of 17%. CAH’s earnings surpassed estimates in the trailing four quarters, the average surprise being 10.3%.
	Saved 2026-07-16 10:29 10d ago Published 2026-07-16 05:00 10d ago	Catholic Health a GE HealthCare uzavírají desetileté partnerství Catholic Health a GE HealthCare uzavřely desetileté partnerství za zhruba 500 milionů USD, které má na Long Islandu rozšířit přístup k pokročilému zobrazování, přesné diagnostice a technologiím umělé inteligence. GEHC GE HealthCare Technologies	FMP Stock News	78
Original source text ROCKVILLE CENTRE, N.Y.--(BUSINESS WIRE)--Catholic Health, an integrated health system located on Long Island, NY, and GE HealthCare (Nasdaq: GEHC) announced today a 10-year strategic partnership, known as a Care Alliance, valued at approximately $500 million, to help expand access to advanced imaging, precision diagnostics and AI-enabled technology across Catholic Health in support of innovative, compassionate and patient-centered care. This will be one of the largest Care Alliances between GE HealthCare and a leading healthcare system in the United States to date; spanning equipment, service, digital solutions, cloud solutions and AI-enabled technologies. The Care Alliance centers on system-wide technology and equipment modernization across key Catholic Health service lines, including cardiology, oncology, neurology, and women’s health. Through this modernization, Catholic Health aims to: Expand Catholic Health’s renowned cardiology practice by extending advanced cardiac imaging to multiple outpatient and ambulatory sites, helping improve access to high-quality cardiac services closer to home. Reduce delays in the oncology care journey by adding MR, CT, and PET technologies equipped with on-device AI solutions, with the goal of decreasing the time from diagnostic imaging to treatment. Expand nuclear medicine capabilities at Catholic Health’s St. Francis Hospital & Heart Center® and Good Samaritan University Hospital flagship locations to enhance diagnostic confidence in oncology. Add hundreds of ultrasound systems to help increase department efficiency and support clinician confidence at the point of care, including at the bedside. Enhance women's health with expanded capabilities in OB/GYN and maternal fetal medicine. A unique aspect of the Care Alliance is an embedded cardiovascular scientist that can work directly with Catholic Health clinicians to help highlight physician perspectives, clinical insights and patient care needs, potentially informing future equipment and technology considerations. “This Care Alliance represents an important investment in the future of health care on Long Island and reflects Catholic Health’s commitment to innovating in ways that improve how care is delivered,” said Gary Havican, Interim President and CEO and Chief Operating Officer of Catholic Health. “By combining Catholic Health’s clinical expertise and commitment to compassionate, high-quality care with GE HealthCare’s advanced technology, AI-driven tools, and digital capabilities, we are enhancing our ability to deliver precision care, expand access to specialized services closer to home, and create a more seamless experience for patients and clinicians. The partnership also gives our physicians and care teams a meaningful voice in shaping the future of care so innovation is guided by real clinical and patient needs.” As part of the 10-year Care Alliance, approximately 50% of equipment additions will arrive at Catholic Health clinical sites during the first three years of the agreement. The agreement is also expected to generate capital savings compared with traditional equipment purchasing approaches thanks to unitary payments and accelerators, which can allow Catholic Health to reinvest resources in technology modernization, expanded patient access and clinical program growth. For patients, the partnership is designed to have a tangible impact on their clinical experience. AI-enabled tools, standardized equipment and more consistent workflows can help Catholic Health to increase capacity, reduce delays in diagnosis and treatment, improve appointment availability, and bring specialized services — including cardiology, neurology, women’s health and cancer care — closer to home. Patients may begin to see benefits during the first year of the agreement with equipment additions expected to arrive within months, including contrast-enhanced mammography to improve access to breast imaging and biopsy services; expanded diagnostic imaging capabilities across multiple modalities; and upgraded maternal-infant care monitoring technologies at Good Samaritan University Hospital. Clinicians will also benefit from enhanced operational support and ongoing collaboration with GE HealthCare experts to help optimize workflows, strengthen clinical decision-making and support innovation. Beyond equipment additions and service line expansion, the Care Alliance includes comprehensive imaging, biomedical maintenance, and service support. A 10-year, multivendor service agreement will cover delivery and maintenance of equipment across 40+ sites, including lifecycle and fleet management, as well as comprehensive education and training. The agreement is designed to support Catholic Health as it maximizes uptime, boosts asset utilization, lowers lifecycle costs, increases operational efficiency, and enhances patient care. This service component helps distinguish the Care Alliance from a traditional equipment agreement, positioning GE HealthCare as a long-term partner in supporting equipment performance and reliability across the system. The Care Alliance will also emphasize AI, cloud, and software solutions designed to deliver actionable insights and drive operational efficiency. Digital solutions included in the Care Alliance aim to reduce manual tasks, ease cognitive load for clinicians, improve clarity for patients, and create a more seamless clinical environment. One example is Imaging 360, a cloud-based radiology operations platform that unifies radiology workflows, centralizes performance insights, and enables remote scanning support. By providing a system-wide view of imaging operations, it can help multi-site health systems improve efficiency, patient access, and care consistency. “This Care Alliance with Catholic Health is grounded in deep collaboration to expand access and advance high-quality care across Long Island,” said Rachel Gilbreath, region president, East, U.S. and Canada at GE HealthCare. “Over the next decade, we will work side-by-side to implement innovative technology and processes across the enterprise, integrate AI, cloud, and software solutions, and support clinical excellence, including cardiology, to position Catholic Health to improve outcomes and operational performance. Together, we are aligning people, process, and technology to deliver measurable impact for patients and clinicians.” Over the course of the Care Alliance, Catholic Health will add expanded capabilities and service lines at St. Francis Hospital & Heart Center®, St. Charles Hospital, Good Samaritan University Hospital, St. Joseph Hospital, St. Catherine of Siena Hospital, and Mercy Hospital, as well as 36 other sites. Equipment will span modalities including CT, PET/CT, nuclear medicine, MR, mammography, X-ray, surgery, ultrasound, women’s health, anesthesia, diagnostic cardiology, and maternal infant care. Catholic Health and GE HealthCare relationship Outside of this agreement, Catholic Health and GE HealthCare have a history of working together on precision care capabilities, including Catholic Health’s early adoption of GE HealthCare’s proprietary PET agent Flyrcado™ (flurpiridaz F 18), which supports greater diagnostic confidence and more personalized care planning. In April 2025, St. Francis Hospital & Heart Center® was the first U.S. site to perform an exercise stress PET myocardial perfusion imaging study using GE HealthCare’s Flyrcado™ (flurpiridaz F 18). For more information about GE HealthCare’s Care Alliances, visit: https://info.gehealthcare.com/carealliance About Catholic Health Catholic Health is an integrated system encompassing some of the region’s finest health and human services agencies. The health system has over 17,000 employees, six acute care hospitals, three nursing homes, a home health service, hospice and a network of physician practices. Under the sponsorship of the Diocese of Rockville Centre, Catholic Health serves hundreds of thousands of Long Islanders each year, providing care that extends from the beginning of life to helping people live their final years in comfort, grace and dignity. For more information, visit: https://www.catholichealthli.org. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™. Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives. Important Safety Information and Usage of Flyrcado™ (flurpiridaz F 18) injection FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION) ™ (flurpiridaz F 18) injection, for intravenous use important safety information Indications and Usage FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION is a radioactive diagnostic drug indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. Contraindications None Warnings and Precautions · Risk associated with exercise or pharmacologic stress: Patients evaluated with exercise or pharmacologic stress may experience serious adverse reactions such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, stroke, and seizure. Perform stress testing in the setting where cardiac resuscitation equipment and trained staff are readily available. When pharmacologic stress is selected as an alternative to exercise, perform the procedure in accordance with the pharmacologic stress agent’s prescribing information. · Radiation risks: FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION contributes to a patient’s overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to minimize radiation exposure to patients and health care providers. Advise patients to hydrate before and after administration and to void. Adverse Reactions · Most common adverse reactions occurring during FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION PET MPI under rest and stress (pharmacologic or exercise) (incidence ≥ 2%) are dyspnea, headache, angina pectoris, chest pain, fatigue, ST segment changes, flushing, nausea, abdominal pain, dizziness, and arrhythmia. Use in Specific Populations · Pregnancy There are no data on use of flurpiridaz F 18 in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. If considering FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from flurpiridaz F 18 and the gestational timing of exposure. FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION contains ethanol (a maximum daily dose of 337 mg anhydrous ethanol). If considering FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes associated with ethanol exposure during pregnancy. · Lactation Temporarily discontinue breastfeeding. A lactating woman should pump and discard breastmilk for at least 8 hours after FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION administration. · Pediatric Use Safety and effectiveness of FLYRCADO™ (FLURPIRIDAZ F 18) INJECTION in pediatric patients have not been established. To report SUSPECTED ADVERSE REACTIONS, contact GE HealthCare at 800-654-0118 (option 2 then option 1) or by email at [email protected] or FDA at 800-FDA-1088 or www.fda.gov/medwatch For full prescribing information, click here. For important safety information, please click here.
	Saved 2026-07-09 20:09 16d ago Published 2026-07-09 14:37 17d ago	GE HealthCare a Mayo Clinic testují léčbu rakoviny prostaty GE HealthCare spolupracuje s Mayo Clinic na studii MI-BET, která má pomocí zobrazování, biomarkerů a dat přizpůsobit radioligandovou terapii pacientům s pokročilým karcinomem prostaty. Využije systém StarGuide SPECT/CT a MIM LesionID Pro k monitorování odpovědi nádoru. GEHC GE HealthCare Technologies	FMP Stock News	78
Original source text Key Takeaways GE HealthCare is collaborating with Mayo Clinic to advance personalized cancer theranostics.The MI-BET study will assess whether imaging, biomarkers and data can tailor RLT cycles.Researchers will use StarGuide SPECT/CT and MIM LesionID Pro to monitor tumor response. GE HealthCare (GEHC - Free Report) has announced a new research collaboration with Mayo Clinic to advance personalized cancer treatment through the MI-BET (Molecular Imaging Biomarker-Based End of Therapy Trial) study. The initiative will evaluate whether imaging, blood-based biomarkers and clinical data can help tailor radioligand therapy for patients with advanced prostate cancer, supporting more adaptive treatment decisions and expanding the use of theranostics. From an investor's perspective, the collaboration reinforces GE HealthCare's growing focus on precision oncology and theranostics, a rapidly evolving area of cancer care. By leveraging its StarGuide SPECT/CT platform and MIM Software's advanced imaging capabilities in a high-profile clinical research setting, the company stands to strengthen the clinical validation and long-term adoption of its imaging technologies. If the study generates favorable evidence, it could enhance GE HealthCare's competitive positioning in molecular imaging, support future demand for its theranostics portfolio and create additional growth opportunities in the expanding precision medicine market. Likely Trend of GEHC Stock Following the NewsShares of GEHC have traded flat since the announcement on July 8. In the year-to-date period, shares of the company have lost 21.2% compared with the industry’s 20.4% decline. The S&P 500 increased 9.9% in the same time frame. In the long term, the collaboration is expected to strengthen GE HealthCare's position in the fast-growing theranostics and precision oncology markets by generating real-world clinical evidence for its advanced molecular imaging technologies. Positive findings from the MI-BET study could accelerate the adoption of the company's StarGuide SPECT/CT platform and MIM Software solutions across healthcare systems, while reinforcing GE HealthCare's role as a strategic partner in data-driven cancer care. The collaboration also enhances the company's innovation pipeline, supports the development of imaging biomarkers and adaptive treatment workflows and could create opportunities for broader commercial adoption as theranostics becomes an increasingly important component of personalized oncology. GEHC currently has a market capitalization of $29.52 billion. Image Source: Zacks Investment Research More on the NewsThe MI-BET study is designed to challenge the conventional approach of administering a fixed number of radioligand therapy cycles by evaluating whether treatment can instead be tailored to an individual patient's response. Using GE HealthCare's StarGuide SPECT/CT system alongside MIM Software's MIM LesionID Pro, researchers will monitor tumor response throughout treatment. By integrating imaging findings with clinical outcomes and blood-based biomarkers, the study aims to determine whether these data-driven insights can guide decisions such as pausing or adapting therapy based on disease progression. Researchers also intend to identify predictive biomarkers that could help physicians anticipate patient response earlier in the treatment journey, enabling more personalized care. The collaboration is also focused on expanding access to advanced theranostics by encouraging broader patient participation through community outreach, partnerships with advocacy organizations and the use of telemedicine to reduce barriers to enrollment. According to Mayo Clinic, the initiative reflects a broader shift toward adaptive, patient-specific cancer care models that seek to optimize treatment effectiveness while minimizing unnecessary therapy. In addition to evaluating treatment duration, the study will investigate novel imaging biomarkers and data-driven approaches that could further enhance clinical decision-making and improve patient outcomes. The research will be conducted at Mayo Clinic's Rochester, MN, campus, combining the organization’s expertise in clinical practice, research and product development. As part of the collaboration, Mayo Clinic has also become the first U.S. site to investigate GE HealthCare's next-generation StarGuide GX SPECT/CT technology, which is designed to improve tumor assessment precision while potentially reducing scan times. Although the StarGuide GX system has received CE Mark certification and is not yet approved for commercial sale in the United States, the collaboration underscores GE HealthCare's commitment to advancing next-generation molecular imaging technologies and supporting the broader adoption of precision oncology solutions. Favorable Industry Prospect for GEHCGoing by the data provided by Precedence Research, the global theranostics market size was calculated at $10.29 billion in 2025 and is predicted to increase from $11.50 billion in 2026 to approximately $31.38 billion by 2035, expanding at a CAGR of 11.8%. The market growth is driven by the rising incidence of chronic diseases, the shift toward personalized medicine, and advances in molecular imaging and radiopharmaceuticals. A Recent Development by GEHCRecently, GEHC announced the Allia platform upgrade pathways to help healthcare providers modernize select legacy Innova and Discovery Image Guiding Solutions systems. The initiative comes as healthcare providers face growing procedural complexity, rising patient volumes and aging imaging equipment. The upgrades enable health systems to access the latest Allia technologies and AI-enabled workflows while preserving existing infrastructure, reducing the need for major construction and minimizing disruption to clinical operations. GEHC’s Zacks Rank & Key PicksCurrently, GEHC carries a Zacks Rank #4 (Sell). Some better-ranked stocks from the broader medical space are Globus Medical (GMED - Free Report) , West Pharmaceutical (WST - Free Report) and Intuitive Surgical (ISRG - Free Report) . Globus Medical, currently carrying a Zacks Rank #2 (Buy), reported a first-quarter 2026 adjusted earnings per share (EPS) of $1.12, which surpassed the Zacks Consensus Estimate by 22.1%. Revenues of $759.9 million beat the Zacks Consensus Estimate by 4.0%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here. GMED has an estimated long-term earnings growth rate of 10.2% compared with the industry’s 12.6% growth. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 26.3%. West Pharmaceutical, currently flaunting a Zacks Rank #1, reported first-quarter 2026 EPS of $2.13, which beat the Zacks Consensus Estimate by 26.8%. Revenues of $844.9 million surpassed the Zacks Consensus Estimate by 8.5%. WST has an estimated long-term earnings growth rate of 13.9% compared with the industry’s 9.5% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 19.4%. Intuitive Surgical, carrying a Zacks Rank #2 at present, reported first-quarter 2026 adjusted EPS of $2.50, which beat the Zacks Consensus Estimate by 20.2%. Revenues of $2.77 billion surpassed the Zacks Consensus Estimate by 6.2%. ISRG has a long-term estimated growth rate of 14.6% compared with the industry’s 12.6% growth. The company’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.8%.
	Saved 2026-06-30 20:33 25d ago Published 2026-06-30 14:20 26d ago	GE HealthCare schválila hotovostní dividendu ve výši 0,035 USD na akcii GE HealthCare schválila hotovostní dividendu ve výši 0,035 USD na akcii za 2. čtvrtletí 2026. Vyplacena bude 14. srpna 2026 akcionářům k 24. červenci 2026. GEHC GE HealthCare Technologies	FMP Stock News	78
Original source text - CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the second quarter of 2026 payable on August 14, 2026, to all shareholders of record as of July 24, 2026. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™. Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives. More News From GE HealthCare Technologies Inc. Back to Newsroom
	Saved 2026-06-29 13:20 27d ago Published 2026-06-29 09:00 27d ago	GE HealthCare modernizuje starší systémy Innova a Discovery GE HealthCare spouští modernizační aktualizaci pro vybrané starší systémy Innova a Discovery IGS, která přidává technologie platformy Allia bez nutnosti velkých stavebních úprav. Program má zlepšit workflow, obrazovou kvalitu a snížit prostoje. GEHC GE HealthCare Technologies	FMP Stock News	78
Original source text CHICAGO--(BUSINESS WIRE)--GE HealthCare today announced Allia™ platform upgrade pathways designed to help customers modernize select legacy Innova™ and Discovery™ Image Guiding Solutions (IGS) systems. These pathways provide access to Allia technologies and workflows that support efficiency and procedural decision-making while helping preserve existing infrastructure, avoid major construction work, extend interventional room lifetime, and minimize disruption to clinical operations. As procedural complexity and patient volumes grow and installed systems age, healthcare providers are looking for flexible ways to modernize interventional environments while balancing operational, infrastructure and capital planning priorities. According to the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR), one-third of interventional X-ray systems in Europe are more than 10 years old, highlighting the importance of technology renewal planning to support increased access to advanced care.i The upgrade pathways can help customers extend the value of existing systems through workflow enhancements, expanded interoperability capabilities and access to Allia innovations, while helping reduce infrastructure replacement needs and support long-term operational and sustainability goals. “Interventional care continues to evolve rapidly, and health systems are looking for technology strategies that balance innovation, operational continuity and long-term value,” said Jyoti Gera, CEO, CardioVascular and Interventional Solutions, Advanced Imaging Solutions, GE HealthCare. “These Allia upgrade pathways reflect our commitment to helping customers modernize on their own terms by extending the capabilities of existing systems while providing access to the latest Allia innovations and AI-enabled technologies in a less disruptive, more sustainable way.” Depending on system configuration, market availability and applicable regulatory requirements, upgrade options may provide access to capabilities and to third party solutions, including: CleaRecon DL,ii an AI-enabled deep learning reconstruction technology designed to support CBCT image interpretation confidence by reducing streak artifacts caused by the pulsatile nature of blood flow during procedures. 3DStent,iii an intraprocedural tool for 3D visualization of the coronary stent designed to remove major stent imaging barriers and provide easy to interpret images. OmnifyXR™ Interventional Suite, an augmented reality guidance solution designed to support workflow efficiency and ergonomics and provide improved visualization and collaborative care for procedures such as prostate embolization.iv Embo ASSIST AI, an augmented guidance solution designed to optimize embolization strategies and streamline clinical workflow.v Medis Quantitative Flow Ratio®vi, a software solution, designed to assess coronary physiology in patients with coronary artery disease. AVVIGO™+ intravascular imaging (IVUS) platformvii multimodality guidance platform that enhances the IVUS and physiology experience and integrates percutaneous coronary intervention tools to support users in the catheterization lab. GE HealthCare also provides Tube Watch and/or OnWatch™ Predict service options on all upgraded systems. These options help customers proactively manage system performance and maintenance by providing an AI-poweredviii estimated lead time to failure, supporting efforts to reduce unplanned downtime. These upgrade pathways are available in the U.S. and other countries where Allia IGS and Allia IGS Pulse systems are available for sale (and have been approved, cleared or registered by the appropriate regulatory authorities). Please contact your local GE HealthCare representative with any questions about this upgrade program. For more information on the available Allia upgrade capabilities, visit: https://www.gehealthcare.com/en-us/services/igs-upgrades. Through GE HealthCare’s upgrade programs, customers can access technology designed to help enhance image quality, expand imaging capabilities with advanced applications, and streamline workflows across image guiding solutions, X-ray, MR and CT systems. These programs are designed to help customers unlock new value from existing systems through smart technology and AI-powered and digital solutions, while supporting productivity, operational continuity and patient-centered care. About GE HealthCare Technologies Inc. GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits. GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™. Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives. i COCIR. 2023. Medical Imaging Equipment Age Profile and Density: 2023 Edition. https://www.cocir.org/wp-content/uploads/23060_COC_X-Ray-INTERVENTIONAL-scaled.jpg. ii CleaRecon DL, designed to be used with Allia systems, is an option in 3DXR designed to be used with Allia systems and requires AW workstation with Volume Viewer. May not be available in all countries. iii 3DStent solution includes Allia™ system, 3DXR and Volume Viewer Innova, and requires AW workstation with Volume Viewer. These applications are sold separately. Not available for sale in all countries. 3DStent is available on Allia™ IGS 5 with 20-cm or 30-cm detector and Allia™ IGS 7 with 30-cm detector. iv OmnifyXR™ Augmented Reality Interventional Suite is a MediView product built in collaboration with and currently exclusively available with compatible GE HealthCare systems. OmnifyXR™ is intended to be used adjunctively to standard of care imaging. Proceduralists must refer to standard of care imaging and prioritize clinical experience and/or judgment when using the OmnifyXR™ system. OmnifyXR™ is not intended to be the sole visualization for any procedure. v Embo ASSIST AI solution includes FlightPlan for Embolization with AI Segmentation option and requires AW workstation with Volume Viewer, Volume Viewer Innova, Vision 2, VesselIQ Xpress, Autobone Xpress. These applications are sold separately. vi Medis QFR® is a product from Medis Medical Imaging. vii AVVIGO+ is an option of Allia IGS 3, Allia IGS 5, Allia IGS 7, Allia IGS 7 OR. AVVIGO™+ is a trademark of Boston Scientific. AVVIGO™+ is manufactured and sold by Boston Scientific and is distributed by GE HealthCare. Refer to your Boston Scientific sales representatives for more information. viii An AI-powered deep machine learning model trained on data from installed systems, leveraging aggregated error logs, parametric data, and historical service activity on eligible systems.